Syntax Bio, the synthetic biology company programming the next generation of stem cell-derived therapies and organoids, has raised $14.4M in a seed funding round. The company is developing a new approach to regenerative medicine discovery and manufacturing.
Its proprietary Cellgorithm platform uses a CRISPR-based system to accelerate and scale stem cell differentiation. This technology aims to replace slow, manual processes with a rapid, programmable method that mimics human development, making cell generation faster, more reliable, and accessible for biopharma developers and patients.
